Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Life & the LawAbortion

Testimony of CLI Associate Scholar Elizabeth Kirk, J.D. before the Pennsylvania House Judiciary Committee

On October 22, 2025, the Pennsylvania House Judiciary Committee held a hearing for House Bill (HB) 1957. HB 1957 is a constitutional amendment that would allow minors to get abortions without parental knowledge or consent, would remove any limiting framework on abortion (e.g., abortion would be legal at any stage of pregnancy), and could lead to taxpayer funding of abortion.

CLI Associate Scholar Elizebeth Kirk, J.D. gave a testimony at the hearing, expertly breaking down the issues with this bill from a legal perspective. She shared how HB 1957’s intent to provide “reproductive liberty” would encompass many things in addition to abortion, including sterilization. In other words, HB 1957 “goes far beyond what Roe did”.

Watch Elizabeth’s testimony below, and click the ‘Print/Download’ button above to access a PDF version of the full written testimony.

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification.

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

A person in a white shirt dropping an abortion ballot into a white box against a yellow background.

Abortion on the Ballot in November

October 2, 2026

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image